Arrowhead Pharmaceuticals, Inc. has announced that its majority-owned subsidiary, Visirna Therapeutics, has signed an asset purchase agreement with Sanofi. Under this deal, Sanofi will acquire rights to develop and commercialize the investigational RNAi therapeutic candidate, plozasiran, in Greater China. Plozasiran is designed to reduce the production of apolipoprotein C-III (APOC3) as a potential treatment for familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG). Visirna will receive an upfront payment of $130 million and may receive additional milestone payments up to $265 million upon regulatory approvals in mainland China. This agreement underscores Visirna's expertise in navigating China's clinical and regulatory landscape, aiming to address unmet needs in cardiometabolic diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.